Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02716766 Phase 2 COMPLETED

The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX) regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.

Details

Lead sponsor	The University of Hong Kong
Phase	Phase 2
Status	COMPLETED
Enrolment	46
Start date	2016-03
Completion	2018-09

Conditions

• Carcinoma, Hepatocellular
• Secondary

Interventions

• Sorafenib
• Capecitabine
• Oxaliplatin

Primary outcomes

• Time to progression (TTP) — Approximately 18 months
  Time from study treatment to radiological progression

Countries

Hong Kong